Cargando…

Case Report: Selexipag in pediatric pulmonary hypertension: Initiation, transition, and titration

Selexipag, a selective prostacyclin receptor agonist, is approved for treating pulmonary arterial hypertension in WHO Group 1 adult patients. Compared to parenteral prostacyclin formulations, selexipag offers a significant improvement in patient’s and caregiver’s quality of life because of its oral...

Descripción completa

Detalles Bibliográficos
Autores principales:	Faircloth, Jenna M., Bhatt, Neelam D., Chartan, Corey A., Coleman, Ryan D., Villafranco, Natalie, Ruiz, Fadel E., Morales-Demori, Raysa, Whalen, Elise, Ely, Erin, Fombin, Rozmeen, Varghese, Nidhy P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pediatrics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10030494/ https://www.ncbi.nlm.nih.gov/pubmed/36969286 http://dx.doi.org/10.3389/fped.2023.1050508

Ejemplares similares

Corrigendum: Case report: Selexipag in pediatric pulmonary hypertension: initiation, transition, and titration
por: Faircloth, Jenna M., et al.
Publicado: (2023)

Prevalence of malnutrition in pediatric pulmonary hypertension cohort and role for registered dietitian involvement
por: Crowell, Presley R., et al.
Publicado: (2023)

Hereditary pulmonary arterial hypertension burden in pediatrics: A single referral center experience
por: Ishizuka, Maki, et al.
Publicado: (2023)

Atrial septal defect closure is associated with improved clinical status in patients ≤ 10 kg with bronchopulmonary dysplasia
por: Webb, Melissa K., et al.
Publicado: (2023)

A Canadian, retrospective, multicenter experience with selexipag for a heterogeneous group of pediatric pulmonary hypertension patients
por: Youssef, David, et al.
Publicado: (2023)

Under Pressure: The Pulmonary Vasculature and Its Role in the Pediatric Cardiac ICU
por: Coleman, Ryan D., et al.
Publicado: (2021)

An Adolescent Patient With Idiopathic Pulmonary Arterial Hypertension Weaned Off Intravenous Epoprostenol Following Treatment With Selexipag: A Case Report
por: Chida-Nagai, Ayako, et al.
Publicado: (2022)

Selexipag for pulmonary arterial hypertension
Publicado: (2021)

Selexipag in the management of pulmonary arterial hypertension: an update
por: Coghlan, J Gerry, et al.
Publicado: (2019)

Selexipag for the treatment of chronic thromboembolic pulmonary hypertension
por: Ogo, Takeshi, et al.
Publicado: (2022)

Hemodynamic and clinical effects of selexipag in children with pulmonary hypertension
por: Rothman, Abraham, et al.
Publicado: (2020)

A Fixed Flow is More Effective than Titrated Flow during Bubble Nasal CPAP for Respiratory Distress in Preterm Neonates
por: Murki, Srinivas, et al.
Publicado: (2015)

Selexipag in the treatment of pulmonary arterial hypertension: design, development, and therapy
por: Hardin, Elizabeth Ashley, et al.
Publicado: (2016)

Baseline history of patients using selexipag for pulmonary arterial hypertension
por: Highland, Kristin B., et al.
Publicado: (2019)

Use of selexipag in a teenage patient with pulmonary arterial hypertension
por: Bravo-Valenzuela, Nathalie Jeanne Magioli, et al.
Publicado: (2021)

Effect of quercetin on the pharmacokinetics of selexipag and its active metabolite in beagles
por: Luo, Shun-bin, et al.
Publicado: (2021)

Transitioning selexipag to oral treprostinil in patients with pulmonary artery hypertension
por: Arevalo, Carlo, et al.
Publicado: (2022)

Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipag
por: Kaufmann, Priska, et al.
Publicado: (2015)

Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension
por: Gaine, Sean, et al.
Publicado: (2017)

Transition from parenteral prostacyclins to selexipag: safety and feasibility in selected patients
por: Aldweib, Nael, et al.
Publicado: (2021)

Pharmacological counseling in hepatotoxicity induced by macitentan and selexipag: a case report
por: Lattanzio, Mariangela, et al.
Publicado: (2022)

Cost-effectiveness analysis of selexipag for the combined treatment of pulmonary arterial hypertension
por: Dong, Wenxing, et al.
Publicado: (2023)

Population Modeling of Selexipag Pharmacokinetics and Clinical Response Parameters in Patients With Pulmonary Arterial Hypertension
por: Krause, A, et al.
Publicado: (2017)

Pulmonary Hypertension Associated with Bronchopulmonary Dysplasia: A Review
por: Varghese, Nidhy, et al.
Publicado: (2019)

Successful transition from Treprostinil to Selexipag in patient with severe pulmonary arterial hypertension
por: Furukawa, Asuka, et al.
Publicado: (2017)

Transition from selexipag to oral treprostinil in a patient with pulmonary arterial hypertension
por: Oriaku, Ifeoma, et al.
Publicado: (2020)

Triple oral combination therapy with macitentan, riociguat, and selexipag for pulmonary arterial hypertension
por: Momoi, Mizuki, et al.
Publicado: (2021)

Impact of additional selexipag on prostacyclin infusion analogs in patients with pulmonary arterial hypertension
por: Momoi, Mizuki, et al.
Publicado: (2022)

Hemodynamic assessment of transitioning from parenteral prostacyclin to selexipag in pediatric pulmonary hypertension
por: Colglazier, Elizabeth, et al.
Publicado: (2022)

The cascade screening in heritable forms of pulmonary arterial hypertension
por: Varghese, Nidhy P., et al.
Publicado: (2023)

Transitioning Stable Patients with Pulmonary Arterial Hypertension from Parenteral Prostanoids to Oral Selexipag
por: Hinkamp, Colin, et al.
Publicado: (2022)

Challenges in Management of VTE in Children With Cancer: Risk Factors and Treatment Options
por: Samji, Nasrin, et al.
Publicado: (2022)

Role of Selexipag in Chronic Obstructive Pulmonary Disease (COPD) Patients With Out-of-Proportion Pulmonary Hypertension
por: Abuserewa, Sherif T, et al.
Publicado: (2021)

Selexipag-based triple combination therapy improves prognosis in Chinese pulmonary arterial hypertension patients
por: Cui, Xiaopei, et al.
Publicado: (2022)

Transitioning intravenous epoprostenol to oral selexipag in idiopathic pulmonary arterial hypertension: a case report
por: Alexandre, André, et al.
Publicado: (2023)

Design of an automatic titrator
por: Migneault, D., et al.
Publicado: (1987)

A PC-based titrator for flow gradient titrations
por: Fuhrmann, B., et al.
Publicado: (1993)

Effects of selexipag and its active metabolite in contrasting the profibrotic myofibroblast activity in cultured scleroderma skin fibroblasts
por: Cutolo, Maurizio, et al.
Publicado: (2018)

Transition from parental prostacyclin to selexipag: a case series of five pulmonary arterial hypertension patients
por: Holthaus, Nathan, et al.
Publicado: (2019)

First-in-child use of the oral selective prostacyclin IP receptor agonist selexipag in pulmonary arterial hypertension
por: Geerdink, Lianne M., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_k0cpirrj1sprr0p4pnserkb2s4